The Bloodwise logo. Bloodwise appears in black text against a white background
Posted by

Metabolism gene linked with poorer cancer outcome

The Bloodwise logo. Bloodwise appears in black text against a white background
Posted by
10 Mar 2016

Some patients with breast cancer, lung cancer and leukaemia are more likely to have a poor disease outcome when a gene usually active only in infancy stays switched on, a new study finds.

Some patients with breast cancer, lung cancer and leukaemia are more likely to have a poor disease outcome when a gene usually active only in infancy stays switched on, a new study finds.

The gene, called CYP3A7, leads to the production of enzymes that break down hormones and around half of all clinically used drugs.

Adults with active copies of the gene have extra capacity to break down hormones and drugs – which could be reducing the effectiveness of some cancer treatments.

Researchers from The Institute of Cancer Research, London, found that 7-8 per cent of around 2,500 cancer patients analysed had a cluster of single-letter variations in the DNA code which allow CYP3A7 to be active in adults. 

If the results are confirmed in other studies, they could help to suggest ways of better optimising cancer treatments for patients with this version of the CYP3A7 gene.

The study, published today (Thursday) in the journal Cancer Research, was funded by organisations including Breast Cancer Now, Bloodwise and Cancer Research UK.

The researchers set out to determine whether the cluster of genetic variants – which had previously been associated both with altered levels of the female sex hormone oestrogen and risk of developing breast cancer – was also associated with an increased risk of poor cancer outcomes.

They carried out a series of analyses on samples from 1,008 women with breast cancer treated at The Royal Marsden hospital, 347 patients with lung cancer and 1,128 with chronic lymphoid leukaemia.

The scientists found that 7-8 per cent of patients in each group – breast cancer, lung cancer and leukaemia – carried a specific single-letter genetic ‘tag’ in their cells which suggested they had the version of the CYP3A7 gene that was still active in adulthood.

They found that among the breast cancer patients, the ‘tag’ was associated with a 74 percent increased risk of death from breast cancer. Among the lung cancer patients, it was associated with a 43 percent increased risk of death from any cause, and among the CLL patients, it was associated with a 62 percent increased risk of disease progression.

They found that in all three groups of cancer patients, the tag was associated with a poor prognosis, possibly because of an effect on the way these patients break down therapeutic cancer drugs. These findings will need to be further tested in carefully designed clinical trials before making any recommendations about changes to patient treatment. However, in the future, it may be possible to tailor chemotherapy regimens to improve outcomes in specific subsets of patients including carriers of the activating genetic variant for CYP3A7, called CYP3A7*1C¬.

Study co-leader Dr Olivia Fletcher, Group Leader in the Breast Cancer Now Research Centre at The Institute of Cancer Research, London, said: “Our study shows that some patients with breast cancer, lung cancer and leukaemia carry a genetic variant which increases their capacity for breaking down hormones – and potentially drugs. We showed that patients with the variant tend to have worse outcomes than those without. One possibility is that they are eliminating chemotherapy drugs from the body too efficiently.

“We will need further studies to determine whether the genetic variant is exercising its effect by interfering with treatment, and if so, exactly how it is affecting treatment. Our research won’t have an immediate impact on clinical practice, but in the longer term, doctors might be able to take into account the presence of this – and other - genetic variants in planning treatment, making sure that all patients have the treatment that is best for them.”

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said: “Initially, research into cancer genetics was largely concerned with establishing the effects on the risk of developing cancer, but there is now increasingly also a focus on finding out how a patient’s genetic background can affect response to treatment.

“This intriguing study suggests that genetic effects on a person’s metabolism, and how they process drugs, could have an impact on their outcome after being diagnosed with cancer. In the future, it is likely that genetic testing will form a much more fundamental part of treatment planning for cancer, so that genetic variants like this can be taken into account in choosing the most effective therapy.”

This News Article originally appeared on the ICR website